Lexeo Therapeutics (NASDAQ:LXEO) Stock Rating Lowered by Wall Street Zen

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a "hold" rating to a "strong sell" rating in a research report issued to clients and investors on Saturday.

• Pharma Frenzy: Volatility Ignites Biotech Sector

Several other equities research analysts have also issued reports on the stock. JPMorgan Chase & Co. reduced their price objective on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an "overweight" rating for the company in a research note on Thursday, June 25th. Chardan Capital upgraded Lexeo Therapeutics to a "strong-buy" rating in a report on Tuesday, July 28th. Finally, Weiss Ratings lowered Lexeo Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Thursday, July 30th. Two equities research analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $18.75.

Read Our Latest Report on LXEO

Lexeo Therapeutics Stock Performance

Shares of LXEO opened at $4.84 on Friday. The firm has a market cap of $380.05 million, a PE ratio of -4.21 and a beta of 1.46. The firm's 50 day moving average price is $4.65 and its 200 day moving average price is $5.63. Lexeo Therapeutics has a twelve month low of $3.99 and a twelve month high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last posted its earnings results on Wednesday, August 12th. The company reported ($0.30) EPS for the quarter, missing the consensus estimate of ($0.29) by ($0.01). On average, sell-side analysts anticipate that Lexeo Therapeutics will post -1.2 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Lexeo Therapeutics news, insider Narinder Pal Bhalla sold 22,306 shares of the business's stock in a transaction on Wednesday, July 1st. The shares were sold at an average price of $4.42, for a total transaction of $98,592.52. Following the completion of the transaction, the insider owned 82,194 shares of the company's stock, valued at $363,297.48. The trade was a 21.35% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Richard Nolan Townsend sold 25,947 shares of the business's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $4.48, for a total transaction of $116,242.56. Following the transaction, the chief executive officer directly owned 377,817 shares of the company's stock, valued at approximately $1,692,620.16. This represents a 6.43% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold a total of 62,204 shares of company stock worth $280,089 over the last quarter. 2.00% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Lexeo Therapeutics

Institutional investors have recently made changes to their positions in the business. Allworth Financial LP increased its position in Lexeo Therapeutics by 1,002.9% in the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company's stock worth $34,000 after buying an additional 3,079 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Lexeo Therapeutics by 69.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company's stock worth $35,000 after buying an additional 1,459 shares during the last quarter. Caitong International Asset Management Co. Ltd bought a new stake in shares of Lexeo Therapeutics in the fourth quarter valued at approximately $37,000. California State Teachers Retirement System boosted its position in shares of Lexeo Therapeutics by 123.7% in the fourth quarter. California State Teachers Retirement System now owns 3,884 shares of the company's stock valued at $39,000 after acquiring an additional 2,148 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in shares of Lexeo Therapeutics by 160.2% in the fourth quarter. Russell Investments Group Ltd. now owns 5,872 shares of the company's stock worth $58,000 after acquiring an additional 3,615 shares during the last quarter. 60.67% of the stock is currently owned by institutional investors.

Lexeo Therapeutics Company Profile

(Get Free Report)

Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.

The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.

Recommended Stories

• Five stocks we like better than Lexeo Therapeutics
• Sony and TSMC’s $4.7 Billion Venture Is About More Than Camera Sensors
• Quantum Leaps: Debt-Free as AI Storage Demand Accelerates
• NVIDIA's $500 Billion GPU Financing Deal Fuels Path Toward $270
• Sandisk’s Margins Look Like Software. Can They Last?

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Lexeo Therapeutics Right Now?

Before you consider Lexeo Therapeutics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Lexeo Therapeutics wasn't on the list.

While Lexeo Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here